You searched for "macula"

687 results found

The International AMD Genomics Consortium study: another success in understanding the complex genetics of AMD

Age-related macular degeneration (AMD) is a neurodegenerative complex disease of the eye and a major cause of blindness and visual impairment among the elderly worldwide. The early stages of the disease are characterised by asymptomatic pigmentary abnormalities and accumulation of...

Eye Capacity: clinical need should drive ophthalmic service provision

Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...

The eye without tears

The Art is long and Life is short. So goes the dispiriting tag in Latin and flung from day one and at regular intervals thereafter at idle medical students who, inevitably brainwashed, come by graduation to believe that the only...

Cortical blindness

Cortical blindness is a rare but recognised entity. Cerebrovascular accident is a well-known risk factor. We report a case of an 84-year-old lady with bilateral cortical blindness with multiple cardiovascular risk factors. Case report An 84-year-old lady was admitted under...

Developments in Ophthalmology: Ophthalmic Radiation Therapy Techniques and Applications

Radiation was discovered by Wilhelm Roentgen in 1895, and since then has been used to treat a variety of cancers. Its therapeutic properties have been widely used for ocular and periocular tumours and inflammatory disease, but the present era is...

Intravitreal Ziv-Aflibercept: safety analysis

Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...

The effects of anti-VEGF therapy for NvAMD on retinal vasculature

This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...

Steroid treatment for pseudophakic cystoid macular oedema

The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...

Treatment of diabetic macular edema in vitrectomised eyes – comparison of intravitreal dexamethasone implant and posterior subtenon triamcinolone injection

This retrospective study was aimed to compare intravitreal dexamethasone implant and posterior subtenon triamcinolone injection (PSTA) in the treatment of diabetic macular edema (DME) in vitrectomised eyes. Sixty-four (48.12%) patients who had received PSTA and 69 (51.88%) patients who had...

Multimodal imaging in wet AMD

This novel study set out to determine grader agreement levels of various retinal imaging techniques, commonly used in the diagnosis of wet age-related macular degeneration (AMD). Images from 52 eyes were by examined by two different observers. All images were...

Cataract surgery in patients being treated for neovascular AMD

This retrospective matched case control study evaluated outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age related macular degeneration (nAMD). They compared 124 patients that had cataract surgery with 372...

Steroid implants in the treatment of post-epiretinal membrane peel macular oedema

This is a retrospective review of 39 eyes of 37 patients treated with Ozurdex® (intravitreal dexamethasone implant) for persistent post-operative cystoid macular oedema (CMO) following vitrectomy and idiopathic epiretinal membrane (ERM) peeling. The 0.7mg implant was injected in each eye...